Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2013. Start Trial.
Date Value
September 30, 2026 103.65M
June 30, 2026 90.26M
March 31, 2026 74.27M
December 31, 2025 70.10M
September 30, 2025 60.48M
June 30, 2025 50.42M
March 31, 2025 42.10M
December 31, 2024 32.22M
September 30, 2024 30.41M
June 30, 2024 26.16M
March 31, 2024 23.54M
December 31, 2023 31.17M
September 30, 2023 30.43M
June 30, 2023 27.99M
March 31, 2023 26.24M
December 31, 2022 16.14M
September 30, 2022 15.66M
June 30, 2022 20.25M
March 31, 2022 29.01M
December 31, 2021 36.45M
September 30, 2021 46.79M
June 30, 2021 65.62M
March 31, 2021 85.04M
December 31, 2020 98.27M
September 30, 2020 106.12M
Date Value
June 30, 2020 100.75M
March 31, 2020 92.24M
December 31, 2019 90.08M
September 30, 2019 81.90M
June 30, 2019 72.55M
March 31, 2019 60.63M
December 31, 2018 48.61M
September 30, 2018 41.12M
June 30, 2018 33.93M
March 31, 2018 29.44M
December 31, 2017 26.04M
September 30, 2017 23.13M
June 30, 2017 21.83M
March 31, 2017 19.63M
December 31, 2016 15.44M
September 30, 2016 11.88M
June 30, 2016 9.199M
March 31, 2016 7.339M
December 31, 2015 5.889M
September 30, 2015 4.637M
June 30, 2015 3.455M
March 31, 2015 1.917M
December 31, 2014 1.256M
September 30, 2014 0.6687M
June 30, 2014 0.2451M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Heron Therapeutics, Inc. 11.93M
Tonix Pharmaceuticals Holding Corp. 80.40M
Karyopharm Therapeutics, Inc. 120.81M
Minerva Neurosciences, Inc. 19.77M
Ocugen, Inc. 45.12M